fls.txt
These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A.


item1.txt
Our effective income tax rate was 23.9 percent and 24.2 percent for the three months ended September 30, 2018 and September 30, 2017, respectively, and 8.4 percent and 12.2 percent for the six months ended September 30, 2018 and September 30, 2017, respectively.
Our effective income tax rate was 23.9 percent and 24.2 percent for the three months ended September 30, 2018 and September 30, 2017, respectively, and 8.4 percent and 12.2 percent for the six months ended September 30, 2018 and September 30, 2017, respectively.
In August 2018, the SEC issued Release No.
Overall, the TCJA resulted in a net tax benefit of $59.
During the six months ended September 30, 2018, we granted non-qualified stock options (“NQSOs”) on 24,940 shares of common stock to eligible employees.
Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.
Contract assets would exist when sales are recorded (i.e.
Mesa Laboratories, Inc.
Our Instruments Division designs, manufactures, and markets quality control instruments and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries.
In August 2018, the SEC issued Release No.
“Commitments and Contingencies” within Item 1.
During the six months ended September 30, 2018, we granted restricted stock units (“RSUs”) on 15,919 shares of our common stock to eligible employees.
Mesa Laboratories, Inc.
The complaint includes counts alleging violations of the Telephone Consumer Protection Act (“TCPA”), the Illinois Consumer Fraud Act, Conversion, Nuisance, and Trespass to Chattels.
The Credit Facility also requires us to maintain a minimum fixed charge coverage ratio of less than 1.25 to 1.0.


item2.txt
Research and development expenses for the three and six months ended September 30, 2018 decreased five percent and 18 percent, respectively, due to streamlining the necessary engineers, materials, and supplies required to support existing businesses.
We are hopeful that we will have new products and services available for sale in the coming year.
“Income Taxes” within Item 1.
Our Cold Chain Monitoring Division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments.
The remaining balance of principal and accrued interest are due on March 1, 2022.
However, the adoption rate of the product has increased over the past year.
Working capital is the amount by which current assets exceed current liabilities.
We typically evaluate costs and pricing annually.
Gross profit is affected by our product mix, manufacturing efficiencies, and price competition.
We plan to make incremental investments in this area over time to further our development plans.
Research and development expenses for the three and six months ended September 30, 2018 decreased five percent and 18 percent, respectively, due to streamlining the necessary engineers, materials, and supplies required to support existing businesses.
We have made no repurchases of our common stock in the current or any of the last three fiscal years.


item3.txt



item4.txt



part2.txt
Part II.


